# **BCC follow up audit**







- 2 projects
- Local Standard Setting in Guideline for follow up of BCC
  Web based survey local standard to be set –
- Audit of 20 successive cases







## Aims and

- To establish the follow up patterns of Basal Cell Carcinoma (BCC) across five cancers networks (ASWCS, 3 Counties, Peninsula, Dorset, Central South Coast)
- To assess if patients follow up in secondary care could be followed up in primary care
- To set standard for BCC follow up in the SW







### Method

- An excel spreadsheet with integrated validation rule to facilitate data collection and analysis of the data.
- All Trusts in the 5 Cancer Networks were asked to participate
- First 20 cases of patients diagnosed in 2004 were to be entered.







# **Results – number of cases**


Cancer Networks	Trusts	Number of cases
ASWCS	North Bristol NHS Trust	21
ASWCS	Royal United Hospital Bath NHS Trust	12
ASWCS	Taunton and Somerset NHS Foundation Trust (inc Yeovil)	20
ASWCS	University Hospitals Bristol NHS Foundation Trust	43
ASWCS	Weston Area Health NHS Trust	26
3 counties	Hereford Hospitals NHS Trust	20
3 counties	Gloucestershire Hospitals NHS Foundation Trust	26
Peninsula	Northern Devon Healthcare NHS Trust	20
Peninsula	Royal Devon and Exeter Hospital NHS Foundation Trust	20
Peninsula	South Devon Healthcare NHS Foundation Trust	41
Central South Coast	Salisbury NHS Foundation Trust	20
Central South Coast	Southampton University Hospitals NHS Trust	15
Thames	Great Western Hospital NHS Foundation Trust	20
Total		304







# Age distribution by gender





## **Travel and self examination**

- Travel (data available for 294 patients)
  - 44% (129/294) of the patients lived within 5 miles of their treatment centre
  - 56% (165/294) lived further away with 9% (26/294) living within 20 to 50 miles from the centre.
- Detection or self examination (data were available for 293 patients)
  - 56% (166/293) detected their own tumour
  - 43% (126/296) of patients were able to self examine themselves with little variation by gender.







# Number of cases in the last 12 months in addition to the index tumour

BCCs	Number of cases
None	174
1	80
2	20
3	9
4-5	6
>5	4
Unknown	11
Total	304







# Histology type of the index lesion

Histology Type	primary	recurrent	unknown	Total
Nodular	122	12		134
Superficial	31	3		34
Morphoeic infiltrative	27	2		29
Micronodular	8	1		9
Not documented	85	6	7	98
Total	273	24	7	304

•41% (122/297) were central face: H zone and 30%(90/297) were other head and neck

- •202 lesions were <2.01cm (88%) & 28 were >2.0cm (12%), data were not available for 74 cases
- •The border of the lesions was distinct in 104 cases (76%) but not distinct in 33 (24%). Data were not available for 166 cases







### Treatment modality of the index lesion

•78%, (237/299) cases had their BCC removed by standard surgical excision.

- •22%, (48/222) cases of the excised BBC lesions needed complex repair
- •78%, (207/266) lesions were fully excised but a total of 22%, (59/266) lesions were not fully excised.
- •80%, (189/233) of those had a excision as their first treatment patients
- •24 lesions were recurrences and of those, 20 of the recurrences were treated by excision while 2 were curetted and on one cryosurgery was performed.







#### Follow up visits

Number of visits	Number of cases
0	62
1	89
2	44
3	1
3 to 5	58
6 to 10	26
11 to 25	14
>25	3
Unknown	7

145 cases were followed up by dermatologists,52 by plastic surgeons, 26 by GPs (some had shared FU).







# Size of first lesion and time lapse in years between final treatment and recurrence

	rec-index tumour			re	rec-other tumour			
Years before recurrence	<2.01	>2.0	Unknown	<2.01	>2.0	Unknown	Total	
0.5	3		3				6	
1	3		1	1			5	
2	2		3	3		2	10	
3	2	1	4			2	9	
4	1					1	2	
5				1			1	
>5	1						1	
Total	12	1	11	5		5	34	







# Time lapse in years between final treatment and recurrence by histology type of index tumour

	Time lapse between final treatment and recurrence (years)							
Histology type	0.5							
Morphoeic infiltrative	1	2						3
Nodular	2	3	5	4	1	1	1	17
Superficial	1			4	1			6
Not documented	2		5	1				8
Total	6	5	10	9	2	1	1	34







# Overall period of fu by histology subtype

		Histology subtype of index tumour									
Period of FU	Nodular	Superficial	Morphoeic infiltrative	Micronodular	Not documente d	Unknown	Total				
0	25	9	8		28	1	71				
0.5	48	10	7	3	27	1	96				
1	13	3	4	1	15		36				
2	19	5	8	1	5		38				
3	6				2	2	10				
4	1	1			1		3				
5	5		1	1	1		8				
>5	15	5	1	2	4		27				
Unknown	2	1		1	4	7	15				
Total	134	34	29	9	87	11	304				







## **Border and FU**

		Border status							
Overall period of FU in Years	distinct	not distinct	not documented	Unknown	Total				
0	29	7	35		71				
0.5	40	11	45		96				
1	13	1	22		36				
2	10	7	19	2	38				
3	1	3	6		10				
4	1		2		3				
5	2	1	5		8				
>5	7	3	17		27				
Unknown	1		8	7	15				
Total	104	33	159	8	304				

7 index tumour with distinct border recurred against 5 with 'no distinct border'







# First modality and period of FU

	First treatment modality									
Overall period of						topical				
FU in Years	cryosurgery	curettage	DXT	excision	Mohs	therapy	Unknown	Total		
0		10	1	59	1			71		
0.5	1	7	3	83	1	1		96		
1		5		30		1		36		
2	1	11	1	25				38		
3	1	2		7				10		
4		1		2				3		
5		2		6				8		
>5		6	1	19		1		27		
Unknown		3	1	6			5	15		
Grand Total	3	47	7	237	2	3	5	304		

9 index tumour treated by curretage recurred against 12 treated by excision and 2 treated by topical therapy





# Site of index tumour and FU

	Site of index tumour								
			other						
Overall period of FU			head and						
in Years	central face	limbs	neck	trunk	Unknown	Total			
0	27	11	21	11	1	71			
0.5	39	13	29	14	1	96			
1	15	7	11	3		36			
2	17	1	13	6	1	38			
3	3	4	3			10			
4	2			1		3			
5	3	1	4			8			
>5	11	3	7	6		27			
Unknown	5	3	2	1	4	15			
Total	122	43	90	42	7	304			

10 index tumours from the central face recurred, 5 from 'other head and neck, 3 limbs and 5 on the trunks





## Other Skin Cancer in the past 5 years

- 31% (86/281) cases were referred back to specialists for possible skin cancer in the last 5 years
- 27% (76/282) cases had one or more BCC in the last 5 years. Of these 46 patients had 2 or more new BCCs within the last 5 years.
- 18/287 had one or more SCC in the last 5 years
- 9 cases had both new BCC and SCC in the last 5 years





